Translational and clinical comparison of whole genome and transcriptome to panel sequencing in precision oncology

被引：0

作者：

Kerle, Irina A. ^{[1
,2
,3
,4
,5
,6
]}

Gross, Thomas ^{[2
,3
,7
]}

Koegler, Anja ^{[2
,3
,7
]}

Arnold, Jonas S. ^{[2
,3
,8
,9
,10
,11
,12
,13
,14
]}

Werner, Maximilian ^{[1
,2
,3
,4
,5
,6
]}

Eckardt, Jan-Niklas ^{[15
,16
]}

Moehrmann, Elena E. ^{[1
,2
,3
,4
,5
,6
]}

Arlt, Marie ^{[2
,3
,8
,9
,10
,11
,12
,13
,14
]}

Hutter, Barbara ^{[17
,18
]}

Huellein, Jennifer ^{[17
,18
]}

Richter, Daniela ^{[1
,4
,5
,19
]}

Schneider, Martin M. K. ^{[15
]}

Hlevnjak, Mario ^{[17
,18
]}

Moehrmann, Lino ^{[1
,2
,3
,4
,5
,6
]}

Hanf, Dorothea ^{[1
,2
,3
,4
,5
,6
]}

Heilig, Christoph E. ^{[20
,21
,22
]}

Kreutzfeldt, Simon ^{[20
,21
]}

Teleanu, Maria-Veronica ^{[20
,21
,22
]}

Schroeck, Evelin ^{[2
,3
,7
,8
,9
,10
,11
,12
,13
,14
]}

Huebschmann, Daniel ^{[17
,18
,23
,24
,25
]}

Horak, Peter ^{[20
,21
]}

Heining, Christoph ^{[1
,2
,3
,4
,5
,6
]}

Froehling, Stefan ^{[20
,21
,23
,26
]}

Glimm, Hanno ^{[1
,2
,3
,4
,5
,6
,19
]}

机构：

[1] UCC, Fac Med, Natl Ctr Tumor Dis Dresden NCT, DKFZ,Dept Translat Med Oncol, Dresden, Germany

[2] Univ Hosp Carl Gustav Carus, TUD Dresden Univ Technol, Dresden, Germany

[3] Helmholtz Zentrum Dresden Rossendorf HZDR, Dresden, Germany

[4] Univ Hosp Carl Gustav Carus, Fac Med, Translat Med Oncol, Dresden, Germany

[5] Univ Hosp Carl Gustav Carus, TUD Dresden Univ Technol, Dresden, Germany

[6] German Canc Consortium DKTK Partner Site Dresden, Partner Site Dresden, Dresden, Germany

[7] UCC, Fac Med, Natl Ctr Tumor Dis NCT, German Canc Res Ctr DKFZ,Core Unit Mol Tumor Diagn, Dresden, Germany

[8] Univ Hosp Carl Gustav Carus, TUD Dresden Univ Technol, Inst Clin Genet, Dresden, Germany

[9] TUD Dresden Univ Technol, Fac Med, Dresden, Germany

[10] Hereditary Canc Syndrome Ctr Dresden, ERN GENTURIS, Dresden, Germany

[11] UCC Dresden, Fac Med, Natl Ctr Tumor Dis Dresden NCT, German Canc Res Ctr DKFZ,NCT, Dresden, Germany

[12] German Canc Consortium DKTK, Dresden, Germany

[13] German Canc Res Ctr, Heidelberg, Germany

[14] Max Planck Inst Mol Cell Biol & Genet, Dresden, Germany

[15] Univ Hosp Carl Gustav Carus Dresden, Dept Internal Med 1, Dresden, Germany

[16] Tech Univ Dresden, Else Kroner Fresenius Ctr Digital Hlth, Dresden, Germany

[17] NCT Heidelberg, Mol Precis Oncol Program, Computat Oncol Grp, Heidelberg, Germany

[18] DKFZ, Heidelberg, Germany

[19] German Canc Res Ctr DKFZ Heidelberg, Div Appl Funct Genom, Heidelberg, Germany

[20] Natl Ctr Tumor Dis NCT Heidelberg, Div Translat Med Oncol, Heidelberg, Germany

[21] German Canc Res Ctr, Heidelberg, Germany

[22] Univ Heidelberg Hosp, Dept Hematol Oncol & Rheumatol, Heidelberg, Germany

[23] German Canc Consortium DKTK, Heidelberg, Germany

[24] DKFZ, Bioinformat & Precis Med BPM, Innovat & Serv Unit, Heidelberg, Germany

[25] Heidelberg Inst Stem Cell Technol & Expt Med, HI STEM, Heidelberg, Germany

[26] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany

来源：

NPJ PRECISION ONCOLOGY | 2025年 / 9卷 / 01期

关键词：

DROSOPHILA-MELANOGASTER; CANCER; PROGRAM; REPAIR; GENE;

D O I：

10.1038/s41698-024-00788-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Precision oncology offers new cancer treatment options, yet sequencing methods vary in type and scope. In this study, we compared whole-exome/whole-genome (WES/WGS) and transcriptome sequencing (TS) with broad panel sequencing by resequencing the same tumor DNA and RNA as well as normal tissue DNA for germline assessment, from 20 patients with rare or advanced tumors, who were originally sequenced by WES/WGS +/- TS within the DKFZ/NCT/DKTK MASTER program from 2015 to 2020. Molecular analyses resulted in a median number of 2.5 (gene panel) to 3.5 (WES/WGS +/- TS) treatment recommendations per patient. Our results showed that approximately half of the therapy recommendations (TRs) of both sequencing programs were identical, while approximately one-third of the TRs in WES/WGS +/- TS relied on biomarkers not covered by the panel. Eight of 10 molecularly informed therapy implementations were supported by the panel, the remaining two were based on biomarkers absent from the panel, highlighting the potential additional clinical benefit of WGS and TS.

引用

页数：10

共 50 条

[41] Comparison of Genotype Imputation for SNP Array and Low-Coverage Whole-Genome Sequencing Data
Deng, Tianyu
Zhang, Pengfei
Garrick, Dorian
Gao, Huijiang
Wang, Lixian
Zhao, Fuping
FRONTIERS IN GENETICS, 2022, 12
[42] Cold Tumour Phenotype Explained Through Whole Genome Sequencing in Clinical Nasopharyngeal Cancer: A Preliminary Study
Handoko
Adham, Marlinda
Rachmadi, Lisnawati
Wibowo, Heri
Gondhowiardjo, Soehartati A.
IMMUNOTARGETS AND THERAPY, 2024, 13 : 173 - 182
[43] Characterisation of invasive clinical Haemophilus influenzae isolates in Queensland, Australia using whole-genome sequencing
Staples, M.
Graham, R. M. A.
Jennison, A. V.
EPIDEMIOLOGY AND INFECTION, 2017, 145 (08) : 1727 - 1736
[44] Porin expression in clinical isolates of Klebsiella pneumoniae: a comparison of SDS-PAGE and MALDI-TOF/MS and limitations of whole genome sequencing analysis
Elias-Lopez, Cristina
Munoz-Rosa, Montserrat
Guzman-Puche, Julia
Perez-Nadales, Elena
Chicano-Galvez, Eduardo
Martinez-Martinez, Luis
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS, 2024, 23 (01)
[45] Identification of Key Regulators of Hepatitis C Virus-Induced Hepatocellular Carcinoma by Integrating Whole-Genome and Transcriptome Sequencing Data
Chen, Guolin
Zhang, Wei
Ben, Yiran
FRONTIERS IN GENETICS, 2021, 12
[46] Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice
Imperial, Robin
Nazer, Marjan
Ahmed, Zaheer
Kam, Audrey E.
Pluard, Timothy J.
Bahaj, Waled
Levy, Mia
Kuzel, Timothy M.
Hayden, Dana M.
Pappas, Sam G.
Subramanian, Janakiraman
Masood, Ashiq
CANCERS, 2019, 11 (09)
[47] The Potential and Limitations of Precision Oncology: Lessons Learned from Whole-Exome Sequencing in an Exceptional Response to Everolimus in Advanced Renal Cell Carcinoma
Pilling, Amanda
Wee, Christopher
Bar-Meir, Eliezer
Dyson, Gregory
Hwang, Ok
Gupta, Nilesh
Chitale, Dhananjay
Hwang, Clara
CASE REPORTS IN ONCOLOGY, 2021, 14 (02): : 1194 - 1200
[48] Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases
Pagnamenta, Alistair T.
Camps, Carme
Giacopuzzi, Edoardo
Taylor, John M.
Hashim, Mona
Calpena, Eduardo
Kaisaki, Pamela J.
Hashimoto, Akiko
Yu, Jing
Sanders, Edward
Schwessinger, Ron
Hughes, Jim R.
Lunter, Gerton
Dreau, Helene
Ferla, Matteo
Lange, Lukas
Kesim, Yesim
Ragoussis, Vassilis
Vavoulis, Dimitrios V.
Allroggen, Holger
Ansorge, Olaf
Babbs, Christian
Banka, Siddharth
Banos-Pinero, Benito
Beeson, David
Ben-Ami, Tal
Bennett, David L.
Bento, Celeste
Blair, Edward
Brasch-Andersen, Charlotte
Bull, Katherine R.
Cario, Holger
Cilliers, Deirdre
Conti, Valerio
Davies, E. Graham
Dhalla, Fatima
Dacal, Beatriz Diez
Dong, Yin
Dunford, James E.
Guerrini, Renzo
Harris, Adrian L.
Hartley, Jane
Hollander, Georg
Javaid, Kassim
Kane, Maureen
Kelly, Deirdre
Kelly, Dominic
Knight, Samantha J. L.
Kreins, Alexandra Y.
Kvikstad, Erika M.
GENOME MEDICINE, 2023, 15 (01)
[49] Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology
Beg, Shaham
Bareja, Rohan
Ohara, Kentaro
Eng, Kenneth Wha
Wilkes, David C.
Pisapia, David J.
Al Zoughbi, Wael
Kudman, Sarah
Zhang, Wei
Rao, Rema
Manohar, Jyothi
Kane, Troy
Sigouros, Michael
Xiang, Jenny Zhaoying
Khani, Francesca
Robinson, Brian D.
Faltas, Bishoy M.
Sternberg, Cora N.
Sboner, Andrea
Beltran, Himisha
Elemento, Olivier
Mosquera, Juan Miguel
TRANSLATIONAL ONCOLOGY, 2021, 14 (01):
[50] Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms
Bartels, Stephan
Schipper, Elisa
Hasemeier, Britta
Kreipe, Hans
Lehmann, Ulrich
ONCOTARGET, 2016, 7 (21) : 30084 - 30093

← 1 2 3 4 5 →